Agenda

Date and TimeTitle
Jun 3, 2022 (Pacific)
7:10am - 7:55am
Taltz: An Overview of Efficacy and Safety in Plaque Psoriasis and Psoriatic Arthritis
This presentation includes a clinical overview of disease manifestations, clinical efficacy, and safety outputs from relevant pivotal trials. The facilitator will provide clinical insights and be available for a live Q&A session following the presentation.
 

This is a NON-CME/CE Presentation.

Sponsored by Lilly

8 days to start
Jun 3, 2022 (Pacific)
7:55am - 8:10am
Break/Visit Exhibits and Poster Hall
8 days to start
Jun 3, 2022 (Pacific)
8:10am - 9:45am
Session I

8:10 AM PT | Welcome/Introductions
Lawrence F. Eichenfield, MD

8:15 AM PT | Biologics and Women
Vivian Shi, MD, FAAD

8:45 AM PT | Atopic Dermatitis: The Latest Developments
Lawrence F. Eichenfield, MD

9:15 AM PT | Case Challenges in Atopic Dermatitis and Psoriasis
Lawrence F. Eichenfield, MD
Vivian Shi, MD

9:30 AM PT | Interactive Panel Discussion
Lawrence F. Eichenfield, MD
Vivian Y. Shi, MD, FAAD

8 days to start
Jun 3, 2022 (Pacific)
9:45am - 10:15am
Break/Visit Exhibits and Poster Hall
9 days to start
Jun 3, 2022 (Pacific)
10:15am - 12:05pm
Session II

10:15 AM PT | Feed Me! Nutritional Approach to Select Skin Diseases
Vivian Shi, MD, FAAD

10:40 AM PT | It's the Pits! Hyperhidrosis and Hidradentitis Suppurativa
George Hightower, MD, PhD

11:05 AM PT | Stop Picking on Me! Acne Across the Lifespan
Linda F. Stein Gold, MD

11:25 AM | New and Emerging Treatments for Scarring & Keloids
Brian R. Berman, MD, PhD

11:50 AM PT | Interactive Panel Discussion
George Hightower, MD, PhD
Brian R. Berman, MD, PhD
Vivian Y. Shi, MD, FAAD
Linda F. Stein Gold, MD

9 days to start
Jun 3, 2022 (Pacific)
12:05pm - 12:15pm
Break/Visit Exhibits and Poster Hall
9 days to start
Jun 3, 2022 (Pacific)
12:15pm - 1:00pm
Challenging AD Expectations
A new therapy option that challenges treatment goals for patients with Refractory, Moderate to Severe Atopic Dermatitis (AD) who are not adequately controlled with other systemic drug products, including Biologics, or when use of those therapies are inadvisable.
 
This is NON CME/CE Presentation.
 
Sponsored by AbbVie
9 days to start
Jun 3, 2022 (Pacific)
1:00pm - 1:20pm
Break/Visit Exhibits and Poster Hall
9 days to start
Jun 3, 2022 (Pacific)
1:20pm - 3:05pm
Session III

1:20 PM PT | Scaling the Heights... and Below: Pediatric Scaling Top to Bottom
Lawrence F. Eichenfield, MD

1:50 PM PT | Should I Send This to the ER? Pediatric Dermatologic Emergencies
George Hightower, MD, PhD

2:20 PM PT | Actinic Keratosis Management: Best Practices
Brian R. Berman, MD, PhD

2:50 PM PT | Interactive Panel Discussion
Brian R. Berman, MD, PhD
George Hightower, MD, PhD
Lawrence F. Eichenfield, MD

9 days to start
Jun 3, 2022 (Pacific)
3:05pm - 3:20pm
Break/Visit Exhibits and Poster Hall
9 days to start
Jun 3, 2022 (Pacific)
3:20pm - 5:05pm
Session IV

3:20 PM PT | Fun in the Sun? Photoprotection Update
Dawn Z. Eichenfield, MD, PhD

3:50 PM PT | AesthPTics: Approaches to the Aging Face
Jacqueline D. Watchmaker, MD

4:20 PM PT | Red Hot and Not: Hemangiomas and Vascular Malformations
Dawn Z. Eichenfield, MD, PhD

4:50 PM PT | Interactive Panel Discussion
Brian R. Berman, MD, PhD
Dawn Z. Eichenfield, MD, PhD
Jacqueline D. Watchmaker, MD
Linda F. Stein Gold, MD

9 days to start
Jun 3, 2022 (Pacific)
5:15pm - 6:00pm
Changing the Paradigm of Retinoid Therapy
Topical retinoids are essential in acne treatment because they target multiple pathways. Tazarotene is considered more efficacious than other retinoids in reducing overall disease severity1. This program will review targeted treatment of acne with tazarotene. [Ref 1: Thielitz A, Gollnick H Am J Clin Dermatol. 2008;9(6):369-381.]
 
This is a NON CME/CE Presentation.
 
Sponsored by Ortho Dermatologics
9 days to start
Jun 4, 2022 (Pacific)
7:10am - 7:55am
Revolutionizing AD: For Children (6-11 Years of Age) with Uncontrolled Moderate to Severe Atopic Dermatitis (AD)
This presentation describes the demonstrated efficacy and safety profile of DUPIXENT in children (6-11 years of age) and the importance of the IL-4/IL-13 pathway in contributing to the pathogenesis of AD. The presentation also highlights the impact of AD in children, along with AD pathophysiology.
 
This is a NON CME/CE Presentation.
 
Sponsored by Regeneron and Sanofi
 
9 days to start
Jun 4, 2022 (Pacific)
7:55am - 8:10am
Break and Visit Exhibits and Poster Hall
9 days to start
Jun 4, 2022 (Pacific)
8:10am - 9:45am
Session V

8:10 AM PT | Welcome Back
Linda F. Stein Gold, MD

8:15 AM PT | Topical Therapy Innovations
Linda F. Stein Gold, MD

8:45 AM PT | Vitiligo Update
Nada Elbuluk, MD, MSc, FAAD

9:15 AM PT | Interactive Panel Discussion
Nada Elbuluk, MD, MSc, FAAD
Linda F. Stein Gold, MD

9 days to start
Jun 4, 2022 (Pacific)
9:45am - 10:00am
Break and Visit Exhibits and Poster Hall
10 days to start
Jun 4, 2022 (Pacific)
10:00am - 12:00pm
Session VI

10:00 AM PT | Seeing Red? Rosacea Update
Linda F. Stein Gold, MD

10:30 AM PT | Hair Today... and Tomorrow: What's New in Hair Disorders
Maria Hordinsky, MD

11:00 AM PT | Skin of Color Spotlight
Nada Elbuluk, MD, MSc, FAAD

11:30 AM PT | Interactive Panel Discussion
Nada Elbuluk, MD, MSc, FAAD
Maria Hordinsky, MD
Linda F. Stein Gold, MD

10 days to start
Jun 4, 2022 (Pacific)
12:00pm - 12:45pm
Mild to Moderate Atopic Dermatitis and the JAK-STAT Pathway
Join Dr. Stein Gold for an informative session on mild to moderate atopic dermatitis and an examination of the efficacy and safety of a potential treatment option.
 
This is a NON CME/CE Presentation. 
 
Sponsored by Incyte
10 days to start
Jun 4, 2022 (Pacific)
12:45pm - 1:15pm
Break/Visit Exhibits and Poster Hall
10 days to start
Jun 4, 2022 (Pacific)
1:15pm - 3:00pm
Session VII

1:15 PM PT | Warts New? Innovations in Treatment in Warts and Molluscum
Shehla Admani, MD

1:40 PM PT | Toxin and Filler Update
Jacqueline Watchmaker, MD

2:10 PM PT | Challenging Cases in Women and Children
Maria Hordinsky, MD

2:40 PM PT | Interactive Panel Discussion
Shehla Admani, MD
Maria Hordinsky, MD
Jacqueline D. Watchmaker, MD

2:55 PM PT | Closing Remarks/Conference Adjourn

10 days to start